Crowcon Detection Instruments appoints global sales director

Graham Franklin gains promotion at gas detection specialist

Gas detection specialist Crowcon Detection Instruments has appointed Graham Franklin as director of global sales.

Franklin has held a number of senior positions at the Abingdon, Oxfordshire, UK based firm. He was most recently sales director for Europe and has also been service manager, USA sales manager and UK sales manager.

Crowcon is a subsidiary of Halma, a leading supplier of portable and fixed gas detection instruments.

You may also like

Regulatory

Crowcon Gas-Pro ensures safety in confined spaces

Gas detector is compact and has a clear display for easy reading
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Regulatory

Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial

The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

From approval to access: the strategic role of packaging in drug launch success

In today’s increasingly complex pharmaceutical landscape, securing regulatory approval is only one milestone on the journey to market
Ingredients

FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars

The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
Subscribe now